Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK)
Betty Lam(Takeda (United States)), Zhe Nie, Ron de Jong(Takeda (United States)), Joanne Miura(Takeda (United States)), Isaac Hoffman(Electronic BioSciences (United States)), Lihong Shi(Sichuan Cancer Hospital), Victoria A. Feher(Schrodinger (United States)), Charles E. Grimshaw(Takeda (United States)), Jennifer Matuszkiewicz(Takeda (United States)), Qing Dong(Fudan University), Masashi Takahashi(Takeda (Japan)), Joshua Cramlett, Jason K. Yano(Fleet Science Center), Ewan R. Taylor(Takeda (United States)), Corey Wyrick(Takeda (United States)), Pamela Farrell(Takeda (United States)), Srinivasa Reddy Natala, Benjamin Jones(Takeda (United States)), Andy Jennings(Takeda (United States)), Yasuyoshi Arikawa(Takeda (Japan)), Hiroshi Miyake(Toyota Memorial Hospital), Jonathan Zalevsky(Nektar Therapeutics (United States))
Cited by 62
Related Papers
The promise and peril of chemical probes
|Nature Chemical Biology|2015|848
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816
Enhanced antibody half-life improves in vivo activity
|Nature Biotechnology|2010|654
Role for Akt3/Protein Kinase Bγ in Attainment of Normal Brain Size
|Molecular and Cellular Biology|2005|549
Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein
|Journal of Biological Chemistry|2011|441